JP7110094B2 - 医薬化合物のアミンプロドラッグ - Google Patents

医薬化合物のアミンプロドラッグ Download PDF

Info

Publication number
JP7110094B2
JP7110094B2 JP2018526135A JP2018526135A JP7110094B2 JP 7110094 B2 JP7110094 B2 JP 7110094B2 JP 2018526135 A JP2018526135 A JP 2018526135A JP 2018526135 A JP2018526135 A JP 2018526135A JP 7110094 B2 JP7110094 B2 JP 7110094B2
Authority
JP
Japan
Prior art keywords
alkyl
aryl
substituted
heteroaryl
metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501877A (ja
JP2019501877A5 (enExample
Inventor
アンソニー・マーファット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of JP2019501877A publication Critical patent/JP2019501877A/ja
Publication of JP2019501877A5 publication Critical patent/JP2019501877A5/ja
Application granted granted Critical
Publication of JP7110094B2 publication Critical patent/JP7110094B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2018526135A 2015-11-19 2016-11-17 医薬化合物のアミンプロドラッグ Active JP7110094B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562257533P 2015-11-19 2015-11-19
US62/257,533 2015-11-19
PCT/US2016/062400 WO2017087594A1 (en) 2015-11-19 2016-11-17 Amine prodrugs of pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2019501877A JP2019501877A (ja) 2019-01-24
JP2019501877A5 JP2019501877A5 (enExample) 2019-12-26
JP7110094B2 true JP7110094B2 (ja) 2022-08-01

Family

ID=58717793

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526135A Active JP7110094B2 (ja) 2015-11-19 2016-11-17 医薬化合物のアミンプロドラッグ

Country Status (8)

Country Link
US (2) US20180318268A1 (enExample)
EP (1) EP3377111B1 (enExample)
JP (1) JP7110094B2 (enExample)
KR (1) KR20180084049A (enExample)
ES (1) ES2969792T3 (enExample)
IL (1) IL259394B (enExample)
SG (2) SG11201803645PA (enExample)
WO (1) WO2017087594A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295942B2 (en) 2015-03-03 2025-05-13 Biohaven Therapeutics Ltd. Riluzole prodrugs and their use
BR112017018832B1 (pt) 2015-03-03 2023-12-26 Biohaven Pharmaceutical Holding Company Ltd Profármacos de riluzol e seu uso e composição
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
US20250049748A1 (en) * 2021-12-16 2025-02-13 Terran Biosciences Inc. Analogs of 4-bromo-2,5-dimethoxyphenethylamine
WO2023141636A1 (en) * 2022-01-24 2023-07-27 Terran Biosciences Inc. Prodrugs of 2-bromo-lsd (2-bromolysergic acid diethylamide)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534312A (ja) 2000-05-26 2003-11-18 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用な環状アミノ酸誘導体
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
JP2008518970A (ja) 2004-11-05 2008-06-05 メルク エンド カムパニー インコーポレーテッド ｛３−［２（ｒ）−［（１ｒ）−１−［３，５−ビス（トリフルオロメチル）フェニル］エトキシ］−３（ｓ）−（４−フルオロフェニル）モルホリン−４−イル］メチル］−５−オキソ−４，５−ジヒドロ−［１，２，４］−トリアゾール−１−イル｝ホスホン酸を調製する方法
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
JP2010539191A (ja) 2007-09-17 2010-12-16 エナンタ ファーマシューティカルズ インコーポレイテッド ６，１１−架橋ビアリールマクロライド
JP2011522838A (ja) 2008-06-06 2011-08-04 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｈｃｖ活性を有する化合物の置換アミノチアゾールプロドラッグ
JP2014533718A (ja) 2011-12-15 2014-12-15 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
US20150111932A1 (en) 2012-05-08 2015-04-23 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
JP2015521598A (ja) 2012-06-11 2015-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ５−［５−フェニル−４−（ピリジン−２−イルメチルアミノ）キナゾリン−２−イル］ピリジン−３−スルホンアミドのホスホロアミド酸プロドラッグ
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US20040176430A1 (en) * 2002-11-21 2004-09-09 Jeffrey Sterling Propargyl-trifluoromethoxy-amino-benzothiazole derivatives
US20130030359A1 (en) * 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
US8937151B2 (en) * 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534312A (ja) 2000-05-26 2003-11-18 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 薬剤として有用な環状アミノ酸誘導体
JP2006510618A (ja) 2002-11-18 2006-03-30 ヤウポン セラピューティクス，インコーポレーテッド ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
JP2008518970A (ja) 2004-11-05 2008-06-05 メルク エンド カムパニー インコーポレーテッド ｛３−［２（ｒ）−［（１ｒ）−１−［３，５−ビス（トリフルオロメチル）フェニル］エトキシ］−３（ｓ）−（４−フルオロフェニル）モルホリン−４−イル］メチル］−５−オキソ−４，５−ジヒドロ−［１，２，４］−トリアゾール−１−イル｝ホスホン酸を調製する方法
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
JP2010539191A (ja) 2007-09-17 2010-12-16 エナンタ ファーマシューティカルズ インコーポレイテッド ６，１１−架橋ビアリールマクロライド
JP2011522838A (ja) 2008-06-06 2011-08-04 アキリオン ファーマシューティカルズ，インコーポレーテッド 抗ｈｃｖ活性を有する化合物の置換アミノチアゾールプロドラッグ
JP2014533718A (ja) 2011-12-15 2014-12-15 アルカーメス ファーマ アイルランド リミテッド 二級アミン化合物のプロドラッグ
US20150111932A1 (en) 2012-05-08 2015-04-23 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
JP2015521598A (ja) 2012-06-11 2015-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ５−［５−フェニル−４−（ピリジン−２−イルメチルアミノ）キナゾリン−２−イル］ピリジン−３−スルホンアミドのホスホロアミド酸プロドラッグ
JP2015524394A (ja) 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2005年，１５，７０９－７１３
Bioorg. Med. Chem. Lett.，2013年，２３，３０２８－３０３３
HOLGER STARK，ENZYME-CATALYZED PRODRUG APPROACHES FOR THE HISTAMINE H3-RECEPTOR AGONIST (R)-α-METHYLHISTAMINE，BIOORGANIC & MEDICINAL CHEMISTRY，2000年12月15日，VOL:9，PAGE(S):191 - 198，https://www.sciencedirect.com/science/article/pii/S0968089600002376?via%3Dihub
J. Heterocyclic Chem.，1985年，２２，４２９－４３２
J. Med. Chem.，1988年，３１，３１８－３２２
JEFFREY J. HALE，PHOSPHORYLATED MORPHOLINE ACETAL HUMAN NEUROKININ-1 RECEPTOR ANTAGONISTS AS WATER-SOLUBLE PRODRUGS，JOURNAL OF MEDICINAL CHEMISTRY，2000年02月25日，VOL:43，PAGE(S):1234 - 1241，http://dx.doi.org/10.1021/jm990617v
Pharm. Res.，1993年，１０，１３５０－１３５５

Also Published As

Publication number Publication date
EP3377111B1 (en) 2023-11-29
EP3377111A4 (en) 2019-11-13
IL259394B (en) 2022-04-01
US20180318268A1 (en) 2018-11-08
IL259394A (en) 2018-07-31
EP3377111A1 (en) 2018-09-26
US20190365721A1 (en) 2019-12-05
ES2969792T3 (es) 2024-05-22
SG10202112588PA (en) 2021-12-30
US11083711B2 (en) 2021-08-10
SG11201803645PA (en) 2018-06-28
KR20180084049A (ko) 2018-07-24
JP2019501877A (ja) 2019-01-24
WO2017087594A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
JP7110094B2 (ja) 医薬化合物のアミンプロドラッグ
ES2646331T3 (es) Procedimiento de síntesis de la ergotioneína y análogos
ES2799409T3 (es) Lípido catiónico
ES2880354T3 (es) Procesos para la síntesis de compuestos de diariltiohidantoína y diarilhidantoína
ES2779225T3 (es) Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos
ES2583375T3 (es) Proceso para la preparación de compuestos nucleósidos 2-desoxi-2-fluoro-2-metil-D-ribofuranosilo
ES2876292T3 (es) Procedimiento de preparación y purificación del antagonista de LFA-1 lifitegrast
ES2407647T3 (es) Método libre de diazonio para obtener un intermediario indazol en la síntesis de amidas de ácido bicíclico 5-(trifluorometoxi)-1H-3-indazol carboxílico
WO2016038045A1 (en) Pyrazolopyridine derivatives and their use in therapy
JP2009511599A5 (enExample)
CA2764425A1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
ES2895487T3 (es) Método de preparación de un inhibidor de la PDE10 ópticamente activo
HRP20170011T1 (hr) Postupak za izradu pemetrekseda i njegove lizinske soli
SK19042001A3 (sk) Spôsob prípravy substituovaných derivátov cyklopentánu a ich nové kryštalické štruktúry
CA3042107C (en) Ire-1.alpha. inhibitors
FR2537974A1 (fr) Nouveaux derives de thieno (2,3-b) pyrrole, leur procede de preparation et les compositions pharmaceutiques les renfermant
ES2894668T3 (es) Procedimiento para preparar éster metílico del ácido 3-[(3s)-7-bromo-2-oxo-5-(piridin-2-il)-2,3-dihidro-1h-[1,4]-benzodiazepin-3-il] propiónico, y compuestos útiles en ese procedimiento
JP2007508301A5 (enExample)
EP1945604A1 (en) Process for the preparation of (omega-aminoalkylamino)alkyl halides and conversion to amifostine
ES2633863T3 (es) Derivado de sulfamida que tiene un grupo adamantilo y una sal farmacéuticamente aceptable del mismo
ES2689447T3 (es) Procedimiento para la preparación de 5-fluorotriptofol
ES2620108T3 (es) Método para preparar la sal de amonio de la fosfomicina
CN107646037A (zh) 选择性合成核苷氨基磷酸酯类化合物的方法
JP2006500409A5 (enExample)
US8937053B2 (en) Process for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220712

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220720

R150 Certificate of patent or registration of utility model

Ref document number: 7110094

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250